Who are TCA treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Anafranil, Amoxan, Surmontil, Zonalon, Triptil, Aventyl.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tca-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

TCA treatment — Competitive Intelligence Brief

TCA treatment (TCA treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tricyclic antidepressant. Area: Psychiatry / Neurology.

marketed Tricyclic antidepressant Norepinephrine transporter (NET), Serotonin transporter (SERT) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

TCA treatment (TCA treatment) — Radboud University Medical Center. TCA treatment refers to tricyclic antidepressant therapy, which blocks the reuptake of norepinephrine and serotonin at neuronal synapses to increase their availability in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TCA treatment TARGET	TCA treatment	Radboud University Medical Center	marketed	Tricyclic antidepressant	Norepinephrine transporter (NET), Serotonin transporter (SERT)
Anafranil	CLOMIPRAMINE	Specgx Llc	marketed	Tricyclic Antidepressant	Sodium-dependent serotonin transporter	1989-01-01
Amoxan	AMOXAPINE	Pfizer	marketed	Tricyclic Antidepressant [EPC]	5-hydroxytryptamine receptor 2A	1980-01-01
Surmontil	TRIMIPRAMINE	Teva Womens	marketed	Tricyclic Antidepressant	Histamine H1 receptor	1979-01-01
Zonalon	DOXEPIN		marketed	Tricyclic Antidepressant	Histamine H1 receptor	1969-01-01
Triptil	PROTRIPTYLINE		marketed	Tricyclic Antidepressant	Adenosine receptor A3	1967-01-01
Aventyl	NORTRIPTYLINE		marketed	Tricyclic Antidepressant	Sodium-dependent noradrenaline transporter	1964-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tricyclic antidepressant class)

Nova Scotia Health Authority · 1 drug in this class
Radboud University Medical Center · 1 drug in this class
University of California, Irvine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TCA treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/tca-treatment. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab